Jerry McMahon

• Discussing the importance of pharma-biotech-academic collaborations and what each sector can provide to successfully create RNA-targeted therapeutics

• How are large pharma and biotech companies structuring risk-sharing partnerships to access innovation and accelerate RNA-targeted therapeutic pipelines

• How can early-stage companies leverage academic collaborations, tool compound sharing and co development deals to validate targets and attract strategic capital

• What trends can be identified from recent investments, M&A activity and deal structures to inform future strategies in RNA therapeutics

• Preclinical data demonstrates that modulating RNA methylation via METTL3 inhibition can enhance tumor sensitivity to treatment and impair resistance mechanisms

• Epitranscriptomic regulation produces durable changes to gene expression and the tumor microenvironment, suggesting anti-cancer efficacy through multiple mechanisms

• STC-15 clinical and translational data point to broad utility of METTL3 inhibition, enabling new treatment approaches across oncology indications